Non-Invasive Monitoring Systems (NIMU) 10-K 30 Oct 17 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jul. 31, 2017	Oct. 17, 2017	Sep. 25, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	NON INVASIVE MONITORING SYSTEMS INC /FL/
Entity Central Index Key	720,762
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jul. 31, 2017
Current Fiscal Year End Date	--07-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 9,200,000
Entity Common Stock, Shares Outstanding		79,007,423
Trading Symbol	NIMU
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Current assets
Cash	$ 11	$ 87
Prepaid expenses, deposits, and other current assets	10	56
Total current assets	21	143
Inventories, net		99
Total assets	21	242
Current liabilities
Notes payable - Related party	1,775	1,675
Notes Payable - other	50	50
Accounts payable and accrued expenses	1,425	1,258
Customer deposits	4	4
Total current liabilities	3,254	2,987
Total liabilities	3,254	2,987
Shareholders' deficit
Common Stock, par value $0.01 per share; 400,000,000 shares authorized; 79,007,423 shares issued and outstanding as of July 31, 2017 and 2016	790	790
Additional paid in capital	21,930	21,930
Accumulated deficit	(26,018)	(25,530)
Total shareholders' deficit	(3,233)	(2,745)
Total liabilities and shareholders' deficit	21	242
Series B Preferred Stock [Member]
Shareholders' deficit
Preferred Stock, value
Series C Preferred Stock [Member]
Shareholders' deficit
Preferred Stock, value	62	62
Series D Preferred Stock [Member]
Shareholders' deficit
Preferred Stock, value	$ 3	$ 3

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	79,007,423	79,007,423
Common stock, shares outstanding	79,007,423	79,007,423
Series B Preferred Stock [Member]
Preferred stock, par value	$ 1	$ 1
Preferred stock, shares authorized	100	100
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100
Preferred stock, liquidation preference	$ 10	$ 10
Series C Preferred Stock [Member]
Preferred stock, par value	$ 1	$ 1
Preferred stock, shares authorized	62,048	62,048
Preferred stock, shares issued	62,048	62,048
Preferred stock, shares outstanding	62,048	62,048
Preferred stock, liquidation preference	$ 62	$ 62
Series D Preferred Stock [Member]
Preferred stock, par value	$ 1	$ 1
Preferred stock, shares authorized	5,500	5,500
Preferred stock, shares issued	2,782	2,782
Preferred stock, shares outstanding	2,782	2,782
Preferred stock, liquidation preference	$ 4,173	$ 4,173

Consolidated Comprehensive Stat

Consolidated Comprehensive Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Revenues
Product sales, net	$ 6	$ 23
Total revenues	6	23
Operating costs and expenses
Cost of sales (including inventory provision of $99 and $327 for 2017 and 2016, respectively)	100	336
Selling, general and administrative	201	259
Total operating costs and expenses	301	595
Operating loss	(295)	(572)
Interest expense, net	(193)	(169)
Net loss	$ (488)	$ (741)
Weighted average number of common shares outstanding - basic and diluted	79,007	79,007
Basic and diluted loss per common share	$ (0.01)	$ (0.01)

Consolidated Comprehensive Sta5

Consolidated Comprehensive Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Income Statement [Abstract]
Provision of Inventory	$ 99	$ 327

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit - USD ($) $ in Thousands	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]	Total
Balance, beginning at Jul. 31, 2015		$ 62	$ 3	$ 790	$ 21,930	$ (24,789)	$ (2,004)
Balance, beginning shares at Jul. 31, 2015	100	62,048	2,782	79,007,423
Net Loss						(741)	(741)
Balance, ending at Jul. 31, 2016		$ 62	$ 3	$ 790	$ 21,930	$ (25,530)	$ (2,745)
Balance, ending shares at Jul. 31, 2016	100	62,048	2,782	79,007,423
Net Loss						$ (488)	$ (488)
Balance, ending at Jul. 31, 2017		$ 62	$ 3	$ 790	$ 21,930	$ (26,018)	$ (3,233)
Balance, ending shares at Jul. 31, 2017	100	62,048	2,782	79,007,423

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Operating Activities
Net loss	$ (488)	$ (741)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1
Write down of inventory	99	327
Changes in operating assets and liabilities
Royalties and other receivables, net		(1)
Inventories, net		9
Prepaid expenses, deposits and other current assets	46	(3)
Accounts payable and accrued expenses	167	130
Net cash used in operating activities	(176)	(278)
Financing Activities
Proceeds from note payable – related party	100	325
Net cash provided by financing activities	100	325
Net (decrease) increase in cash	(76)	47
Cash, beginning of year	87	40
Cash, end of year	$ 11	$ 87

Organization and Business

Organization and Business	12 Months Ended
	Jul. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	1. ORGANIZATION AND BUSINESS Organization. ® Business. ® The Company received revenue from royalties on sales of diagnostic monitoring hardware and software by SensorMedics and from VivoMetrics in prior years. SensorMedics indicated they will discontinue licensed product sales after current inventory is depleted and, therefore, the royalty revenue from SensorMedics is expected to be minimal to none. VivoMetrics ceased operations in July 2009 and filed for Chapter 11 bankruptcy protection in October 2009. Pursuant to VivoMetrics’ approved bankruptcy plan of reorganization, our license with VivoMetrics was assigned to another company; however, there can be no assurance as to the future amount of royalty revenue, if any, that we may derive from this license or from our existing license with SensorMedics. In fiscal year 2009, NIMS began commercial sales of its third generation Exer-Rest therapeutic platforms. During the calendar years 2005 to 2007, the Company designed, developed and manufactured the first Exer-Rest platform (now the Exer-Rest AT), a second generation acceleration therapeutics platform, and updated its operations to promote the Exer-Rest AT overseas as an aid to improve circulation and joint mobility and to relieve minor aches and pains. The Company has developed a third generation of Exer-Rest acceleration therapeutic platforms (designated the Exer-Rest AT3800 and the Exer-Rest AT4700) that had been manufactured by Sing Lin Technologies Co. Ltd. (“Sing Lin”) based in Taichung, Taiwan (see Note 9). Management has restated the components of equity for all periods presented to reclassify the comprehensive loss on the consolidated statements of changed in shareholders’ deficit to accumulated deficit. This was to reflect the substantial liquidation of its investment in NIMS Canada which would have resulted in the comprehensive loss being reclassified into earnings previously. Management does not believe this restatement is material to any period presented or to prior financial statements issued. The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. As reflected in the accompanying consolidated financial statements, the Company had net losses in the amount of $0.5 and $0.7 million for the years ended July 31, 2017 and 2016, respectively, and has experienced negative cash outflows from operating activities. The Company also has an accumulated deficit of $26.0 million as of July 31, 2017, and has purchase commitments at July 31, 2017 (see Note 9). These matters raise substantial doubt about the Company’s ability to continue as a going concern. will need to incur additional debt, equity financing or a strategic collaboration for the Company to continue its business activities, which are currently focused on strategic collaborations and commercial sale of the Exer-Rest. Management intends to obtain any additional capital needed to continue its business activities through new debt or equity financing, but there can be no assurance that it will be successful in this regard. The accompanying consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. As further discussed in Note 9, the Company in 2010 terminated its agreement with Sing Lin. As of July 31, 2017, the Company has payables due to Sing Lin of approximately $41,000.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation. Use of Estimates. Cash and Cash Equivalents. Allowances for Doubtful Accounts. Inventories. Tooling and Equipment. Long-lived Assets. Taxes Assessed on Revenue-Producing Transactions. Income Taxes. Revenue Recognition. Advertising Costs. Research and Development Costs. Warranties. Stock-based compensation. Fair Value of Financial Instruments. As of July 31, 2017 and 2016, the respective carrying value of the notes payable – related party and notes payable – other approximate our current borrowing rate for similar debt instruments of comparable maturity and are considered Level 3 measurements within the fair value hierarchy. Comprehensive Income (Loss). Loss Contingencies. Recent Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases Leases In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230)

Inventories

Inventories	12 Months Ended
	Jul. 31, 2017
Inventory Disclosure [Abstract]
Inventories	3. INVENTORIES The Company’s inventory consists of the following (in thousands): July 31, 2017 July 31, 2016 Work-in-progress, including accessories and spare parts $ – $ – Finished goods – 99 Total inventories $ – $ 99 The Company recorded inventory valuation adjustments of $99,000 and $327,000 for the years ended July 31, 2017 and 2016. The $99,000 and $327,000 inventory valuation adjustment for the year ended July 31, 2017 and 2016, respectively, resulted from management’s business review and related assessment of the net realizable value of the Exer-Rest units. Factors in this determination included the age of inventory, recent historical sales, and the uncertainty of when the Company would have a sales team, either internal or through an alliance or collaboration, for the Exer-Rest. In light of the change in circumstances in connection with management’s business review which included a decision to not pursue re-hiring a sales force or such other alternatives in the foreseeable future, management reassessed its inventory valuation and recorded a provision on inventory.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Jul. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	4. STOCK-BASED COMPENSATION The Company measures the cost of employee, officer and director services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. The Company did not record any stock based compensation expense for the years ended July 31, 2017 and 2016. The Company’s 2000 Stock Option Plan, as amended (the “2000 Plan”), provides for the issuance of up to 2,000,000 shares of the Company’s common stock. The 2000 Plan allows the issuance of incentive stock options, stock appreciation rights and restricted stock awards. The exercise price of the options is determined by the compensation committee of the Company’s Board of Directors, but incentive stock options, if any, must be granted at an exercise price not less than the fair market value of the Company’s common stock as of the grant date or an exercise price of not less than 110% of the fair value for a 10% shareholder. Options expire up to ten years from the date of the grant and are exercisable according to the terms of the individual option agreements. The 2000 Plan has expired and no future grants can be made from the 2000 Plan; however, previously granted options will remain in force pursuant to the terms of the individual grants. In November 2010, the Board and Compensation Committee approved the Non-Invasive Monitoring Systems, Inc. 2011 Stock Incentive Plan (the “2011 Plan”). Awards granted under the 2011 Plan may consist of incentive stock options, stock appreciation rights (SAR), restricted stock grants, restricted stock units (RSU) performance shares, performance units or cash awards. The 2011 Plan authorizes up to 4,000,000 shares of our common stock for issuance pursuant to the terms of the 2011 Plan. The 2011 Plan was approved by our shareholders in March 2012 and no awards have been granted under the 2011 Plan as of July 31, 2017. The Company did not grant any stock options for the years ended July 31, 2017 and 2016. A summary of the Company’s stock option activity for the years ended July 31, 2017 and 2016 is as follows: Shares Weighted Average Exercise Price Weighted average remaining contractual term (years) Aggregate Intrinsic Value Options outstanding, July 31, 2015 378,750 $ 0.38 Options granted – $ 0.000 Options exercised – $ 0.000 Options expired 178,750 $ 0.000 Options outstanding, July 31, 2016 200,000 $ 0.430 Options granted – $ – Options exercised – $ – Options expired 200,000 $ 0.430 Options outstanding, July 31, 2017 – $ – – $ – Options expected to vest, July 31, 2017 – $ – – $ – Options exercisable, July 31, 2017 – $ – – $ – All of the options outstanding at July 31, 2017 and 2016 were issued under the 2000 Plan. There were no options forfeited or exercised for the year ended July 31, 2017 and 2016. As of July 31, 2017, there were no unrecognized costs related to outstanding stock options.

Notes Payable

Notes Payable	12 Months Ended
	Jul. 31, 2017
Debt Disclosure [Abstract]
Notes Payable	5. NOTES PAYABLE 2010 Credit Facility 2011 Promissory Notes. 2012 Promissory Note. 2013 Promissory Note. 2014 Promissory Note. 2015 Promissory Notes. On April 16, 2015, we entered into a promissory note (“April 2015 Frost Note”) in the amount of $100,000 with Frost Gamma, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock. The interest rate payable by the Company on the April 2015 Frost Note is 11% per annum, originally payable on the maturity date of July 31, 2015 and subsequently the date was extended to July 31, 2018. The April 2015 Frost Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty. On August 12, 2015, we entered into a promissory note in the principal amount of $25,000 with Frost Gamma (the “August 2015 Frost Note”), a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock. The interest rate payable by the Company on the August 2015 Frost Note is 11% per annum, originally payable on the maturity date of July 31, 2017 and subsequently the date was extended to July 31, 2018. The August 2015 Frost Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty. On October 27, 2015, the Company entered into a promissory note in the principal amount of $50,000 with Frost Gamma (the “October 2015 Frost Gamma Note”), a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock. The interest rate payable by the Company on the October 2015 Frost Gamma Note is 11% per annum, originally payable on the maturity date of July 31, 2017 and subsequently the date was extended to July 31, 2018. The October 2015 Frost Gamma Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty. On October 27, 2015, the Company entered into a promissory note in the principal amount of $50,000 with Jane Hsiao, the Company’s Chairman of the Board and Interim Chief Executive Officer (the “October 2015 Hsiao Note”). The interest rate payable by the Company on the October 2015 Hsiao Note is 11% per annum, originally payable on the maturity date of July 31, 2017 and subsequently the date was extended to July 31, 2018. The October 2015 Hsiao Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty. 2016 Promissory Notes. On June 1, 2016, the Company entered into a promissory note in the principal amount of $100,000 with Hsu Gamma, an entity controlled by NIMS’ Chairman of the Board and Interim Chief Executive Officer, Jane H. Hsiao, (the “June 2016 Hsu Gamma Note”). The interest rate payable by NIMS on the June 2016 Hsu Gamma Note is 11% per annum, originally payable on the maturity date of July 31, 2017 and subsequently the date was extended to July 31, 2018. The June 2016 Hsu Gamma Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty. 2017 Promissory Notes. On April 6, 2017, the Company entered into a promissory note in the principal amount of $50,000 with Hsu Gamma, an entity controlled by NIMS’ Chairman of the Board and Interim Chief Executive Officer, Jane H. Hsiao, (the “April 2017 Hsu Gamma Note”). The interest rate payable by NIMS on the 2017 Hsu Gamma Note is 11% per annum, originally payable on the maturity date of July 31, 2017 and subsequently the date was extended to July 31, 2018. The 2017 Hsu Gamma Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty. On September 22, 2017, the Company entered into a promissory note in the principal amount of $50,000 with Frost Gamma (the “September 2017 Frost Gamma Note”), a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock. The interest rate payable by the Company on the 2017 Frost Gamma Note is 11% per annum, payable on the maturity date of July 31, 2018. The 2017 Frost Gamma Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty. On September 22, 2017, the Company entered into a promissory note in the principal amount of $50,000 with Hsu Gamma, an entity controlled by NIMS’ Chairman of the Board and Interim Chief Executive Officer, Jane H. Hsiao, (the “September 2017 Hsu Gamma Note”). The interest rate payable by NIMS on the 2017 Hsu Gamma Note is 11% per annum, payable on the maturity date of July 31, 2018. The 2017 Hsu Gamma Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty. As of the date these financial statements are issued, the Company was obligated under the above described Credit Facility and Promissory Notes to make future principal payments (excluding interest) as follows: Year Ending July 31, 2018 1,925,000 $ 1,925,000

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Jul. 31, 2017
Equity [Abstract]
Shareholders' Equity	6. SHAREHOLDERS’ EQUITY The Company has three classes of Preferred Stock. Holders of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters. Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $100 per share, plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $10 per share, if declared. Series C Preferred Stock is redeemable by the Company at a price of $0.10 per share upon 30 days prior written notice. This series has a liquidation value of $1.00 per share plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $0.10 per share, if declared. Each share of Series C Preferred Stock is convertible into 25 shares of the Company’s common stock upon payment of a conversion premium of $4.20 per share of common stock. The conversion rate and the conversion premium are subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. Series D Preferred Stock is not redeemable by the Company. This series has a liquidation value of $1,500 per share, plus declared and unpaid dividends, if any. Each share of Series D Preferred Stock is convertible into 5,000 shares of the Company’s common stock. The conversion rate is subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. The Company issued 65,000 shares of the Company’s common stock for the conversion of 13 shares of Series D Preferred Stock during the twelve months ended July 31, 2016 and did not issue any shares of the Company’s common stock for the twelve months ended July 31, 2017. No preferred stock dividends have been declared as of July 31, 2017 or 2016.

Basic and Diluted Loss Per Shar

Basic and Diluted Loss Per Share	12 Months Ended
	Jul. 31, 2017
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Share	7. BASIC AND DILUTED LOSS PER SHARE Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the years ended July 31, 2017 and 2016, no dilution adjustment has been made to the weighted average outstanding common shares because the assumed exercise of outstanding options and warrants and the conversion of preferred stock would be anti-dilutive. Potential common shares not included in calculating diluted net loss per share are as follows: July 31, 2017 July 31, 2016 Stock options – 200,000 Series C Preferred Stock 1,551,200 1,551,200 Series D Preferred Stock 13,910,000 13,910,000 Total 15,461,200 15,661,200

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jul. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	8. RELATED PARTY TRANSACTIONS Dr. Hsiao, Dr. Frost and directors Steven Rubin and Rao Uppaluri are each stockholders, current or former officers and/or directors or former directors of TransEnterix, Inc. (formerly SafeStitch Medical, Inc.) (“TransEnterix”), a publicly-traded, Cogint, Inc. (“Cogint”) (formerly known as IDI, Inc.), a publicly-traded data fusion company and VBI Vaccines Inc, a vaccine development company. The Company’s Chief Financial Officer also served as the Chief Financial Officer of TransEnterix until October 2, 2013. The Company’s Chief Financial Officer continued as an employee of TransEnterix until March 3, 2014, during which he supervised the Miami based accounting staff of TransEnterix under a cost sharing arrangement whereby the total salaries of the Miami based accounting staff was shared by the Company and TransEnterix. Since December 2009, the Company’s Chief Legal Officer has served under a similar cost sharing arrangement as Corporate Counsel of Cogint and as the Chief Legal Officer of TransEnterix. The Company recorded additions to selling, general and administrative costs and expenses to account for the sharing of costs under these arrangements of $5,000 for the years ended July 31, 2017 and 2016, respectively. Aggregate accounts payable to TransEnterix totaled approximately $800 and $800 at July 31, 2017 and 2016, respectively. The Company signed a five year lease for office space in Miami, Florida with a company controlled by Dr. Phillip Frost, who is the beneficial owner of more than 10% of the Company’s common stock. The rental payments under the Miami office lease, which commenced January 1, 2008 and expired on December 31, 2012, were approximately $1,250 per month and then continued on a month-to-month basis. In February 2016 the rent was reduced to $0 per month. For the years ended July 31, 2017 and 2016, the Company recorded rent expense related to the Miami lease of $0 and $9,000, respectively. At July 31, 2017 and 2016, approximately $76,000 and $76,000 in rent was payable. The Company signed a three year lease for warehouse space in Hialeah, Florida with a company jointly controlled by Dr. Frost and Dr. Jane Hsiao, the Company’s Chairman and Interim CEO. The rental payments under the Hialeah warehouse lease, which commenced February 1, 2009 and expired on January 31, 2012, were approximately $5,000 per month for the first year and were subsequently on a month-to-month basis following the expiration of the lease. As further described in Note 9, the Company vacated the Hialeah warehouse in September 2014 and entered into a new lease with an unrelated third party. The Company recorded $0 of rent expense related to the Hialeah lease for the years ended July 31, 2017 and 2016, respectively. At July 31, 2017 and 2016, approximately $115,000 in rent was payable. The Company has the Credit Facility and multiple notes payable outstanding to related parties, as more fully described in Note 5 to these consolidated financial statements. The Company incurred interest expense related to the Credit Facility of approximately $110,000 for the years ended July 31, 2017 and 2016, respectively. The Company also incurred interest expense related to the promissory notes of approximately $83,000 and $59,000 for the years ended July 31, 2017 and 2016, respectively. A total of $1.0 million and $810,000 in accumulated interest payable on the Credit Facility and promissory notes remained outstanding as of July 31, 2017 and July 31, 2016, respectively. NIMS is under common control with multiple entities and the existence of that control could result in operating results or financial position of each individual entity significantly different from those that would have been obtained if the entities were autonomous. One of those related parties, OPKO Health, Inc. and NIMS are under common control and OPKO Health, Inc. has a one percent ownership interest in NIMS that OPKO has accounted for as an equity method investment due to the ability to significantly influence NIMS.

Commitments

Commitments	12 Months Ended
	Jul. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments	9. COMMITMENTS Leases The Company is under an operating lease agreement for office space that expired in 2012 and continued on a month to month basis. In February 2016 the office space rent was reduced to $0 per month. We house our inventory in approximately 4,000 square feet of warehouse space in Pembroke Park, Florida. The lease commenced September 15, 2014 and originally expired on September 30, 2015 and we have exercised our options to renew that extends the expiration to September 15, 2017. We are in the process of negotiating to extend our lease. Generally, the lease agreements require the payment of base rent plus escalations for increases in building operating costs and real estate taxes. Rental expense under these operating leases amounted to $44,000 and $52,000 for the years ended July 31, 2017 and 2016, respectively. Product Development and Supply Agreement. In September 2007, the Company entered into a Product Development and Supply Agreement (the “Agreement”) with Sing Lin Technologies Co. Ltd., a company based in Taichung, Taiwan (“Sing Lin”). Pursuant to the Agreement, the Company consigned to Sing Lin the development and design of the next generation Exer-Rest and related devices. The Agreement commenced as of September 3, 2007 and had a term that extended three years from the acceptance by NIMS of the first run of production units. Thereafter, the Agreement automatically renewed for successive one year terms unless either party sent the other a notice of non-renewal. Either party was permitted to terminate the Agreement with ninety days prior written notice. Upon termination, each party’s obligations under the Agreement were to be limited to obligations related to confirmed orders placed prior to the termination date. Pursuant to the Agreement, Sing Lin designed, developed and manufactured the tooling required to manufacture the acceleration therapeutic platforms for a total cost to the Company of $471,000. Sing Lin utilized the tooling in the performance of its production obligations under the Agreement. The Company paid Sing Lin $150,000 of the tooling cost upon execution of the Agreement and $150,000 upon the Company’s approval of the product prototype concepts and designs. The balance of the final tooling cost became due and payable in September 2008 upon acceptance of the first units produced using the tooling, and was paid in full during the year ended July 31, 2009. Under the now-terminated Agreement, the Company also granted Sing Lin the exclusive distribution rights for the products in certain countries in the Far East, including Taiwan, China, Japan, South Korea, Malaysia, Indonesia and certain other countries. Sing Lin agreed not to sell the Products outside its geographic areas in the Far East. The Agreement provided for the Company to purchase approximately $2.6 million of Exer-Rest units within one year of the September 2008 acceptance of the final product. The Agreement further provided for the Company to purchase $4.1 million and $8.8 million of Exer-Rest products in the second and third years following such acceptance, respectively. These minimum purchase amounts were based upon 2007 product costs multiplied by volume commitments. Through July 31, 2017, the Company had paid Sing Lin $1.7 million in connection with orders placed through that date. As of July 31, 2017, the Company has approximately $41,000 of payables due to Sing Lin. As of July 31, 2017, aggregate minimum future purchases under the Agreement totaled approximately $13.9 million. As of July 31, 2017, the Company had not placed orders sufficient to meet the first-year or second-year minimum purchase obligations under the Agreement. The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement. As of October 24, 2017 Sing Lin has not followed up on its July 2010 demand. There can be no assurance that Sing Lin will not attempt to enforce its remedies under the Agreement, or pursue other potential remedies.

Long-Lived Assets

Long-Lived Assets	12 Months Ended
	Jul. 31, 2017
Property, Plant and Equipment [Abstract]
Long-Lived Assets	10. LONG-LIVED ASSETS The Company’s long-lived assets include furniture and equipment, computers, tooling, websites and software, leasehold improvements, patents and trademarks. Tooling and equipment, net of accumulated depreciation, consisted of the following at July 31, 2017 and 2016 (in thousands): Estimated Useful Life July 31, 2017 July 31, 2016 Furniture and fixtures, leasehold improvements, office equipment and computers 3 – 5 years $ 85 $ 85 Website and software 3 years 26 26 111 111 Less accumulated depreciation (111 ) (111 ) Tooling and equipment, net $ 0 $ 0 Depreciation expense was $0 for the years ended July 31, 2017 and 2016, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	11. INCOME TAXES The Company accounts for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The accounting for uncertain tax positions guidance under ASC 740 requires that we recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The application of this guidance does not impact the Company’s financial position, results of operations or cash flows for the years ended July 31, 2017 and 2016. The Company files its tax returns in the U.S. federal jurisdiction, Canada federal jurisdiction and with various U.S. states and the Ontario province of Canada. The Company is subject to tax audits in all jurisdictions for which it files tax returns. Tax audits by their very nature are often complex and can require several years to complete. There are currently no tax audits that have commenced with respect to income tax or any other returns in any jurisdiction. Tax years ranging from 2014 to 2017 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. Because the Company is carrying forward income tax attributes, such as net operating losses and tax credits from 2013 and earlier tax years, these attributes can still be audited when utilized on returns filed in the future. It is the Company’s policy to include income tax interest and penalties expense in its tax provision. The difference between income taxes at the statutory federal income tax rate and income taxes reported in the consolidated comprehensive statements of operations are attributable to the following (in thousands): July 31, 2017 July 31, 2016 Income tax benefit at the federal statutory rate $ (166 ) $ (252 ) State and local income taxes, net of effect of federal taxes 10 (27 ) Stock-based compensation 272 – (Decrease) Increase in valuation allowance (116 ) 279 Provision for income tax $ – $ – The tax effects of temporary differences that give rise to significant portions of the deferred tax assets consist of the following (in thousands): July 31, 2017 July 31, 2016 Federal and State net operating loss $ 5,988 $ 5,847 Foreign net operating loss 18 18 Stock-based compensation and other 173 430 6,179 6,295 Less: Valuation allowance (6,179 ) (6,295 ) Net deferred tax asset $ – $ – At July 31, 2017, the Company had available Federal and State net operating loss carry forwards of approximately $15.9 million and foreign net operating loss carry forwards of approximately $0.1 million which expire in various years beginning in 2019. Total Federal and State net operating loss carry forwards include approximately $2.0 million generated from the exercise of non-statutory stock options. The net operating loss carry forwards may be subject to limitation due to change of ownership provisions under section 382 of the Internal Revenue Code and similar state provisions. A valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, management has determined that a full $6.2 million valuation allowance at July 31, 2017 ($6.3 million at July 31, 2016) was necessary. The increase (decrease) in the valuation allowance for the years ended July 31, 2017 and 2016 were approximately ($116,000) and $279,000, respectively. The Company paid no taxes in the years 2017 or 2016.

Risks and Uncertainties and Con

Risks and Uncertainties and Concentrations of Risk	12 Months Ended
	Jul. 31, 2017
Risks and Uncertainties [Abstract]
Risks and Uncertainties and Concentrations of Risk	12. RISKS AND UNCERTAINTIES AND CONCENTRATIONS OF RISK Financial instruments that potentially subject the Company to risk consist principally of cash, royalties and other receivables, and purchases and advances to contract manufacturer. Inventories: The provision on inventory is an estimate based on multiple factors as further described in Note 3. The ultimate realization of the inventory amounts may be materially different. During 2016, the Company did not renew its FDA registration for the Exer-Rest and as of the date of these financial statements, the Company had started the process to renew its registration and does not anticipate any significant delays or effects on operations. If the registration were to be rejected or significantly delayed, the Company’s sales could be affected. Also, during 2016, the Company did not renew its International Organization for Standardization (“ISO”) certification which could prevent sales from being permitted in Europe and other areas that may require ISO certification. The Company does not anticipate this will significantly affect its expected revenues, in part because the Company does not anticipate significant potential future revenues from Europe. Royalties and Other Receivables. Purchases from and Advances to Contract Manufacturer. Major Customers.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Consolidation	Consolidation.
Use of Estimates	Use of Estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents.
Allowances for Doubtful Accounts	Allowances for Doubtful Accounts.
Inventories	Inventories.
Tooling and Equipment	Tooling and Equipment.
Long-lived Assets	Long-lived Assets.
Taxes Assessed on Revenue-Producing Transactions	Taxes Assessed on Revenue-Producing Transactions.
Income Taxes	Income Taxes.
Revenue Recognition	Revenue Recognition.
Advertising Costs	Advertising Costs.
Research and Development Costs	Research and Development Costs.
Warranties	Warranties.
Stock-based Compensation	Stock-based compensation.
Fair Value of Financial Instruments	Fair Value of Financial Instruments. As of July 31, 2017 and 2016, the respective carrying value of the notes payable – related party and notes payable – other approximate our current borrowing rate for similar debt instruments of comparable maturity and are considered Level 3 measurements within the fair value hierarchy.
Comprehensive Income (Loss)	Comprehensive Income (Loss).
Loss Contingencies	Loss Contingencies.
Recent Accounting Pronouncements	Recent Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases Leases In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230)

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jul. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory	The Company’s inventory consists of the following (in thousands): July 31, 2017 July 31, 2016 Work-in-progress, including accessories and spare parts $ – $ – Finished goods – 99 Total inventories $ – $ 99

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Jul. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation Stock Options Activity	A summary of the Company’s stock option activity for the years ended July 31, 2017 and 2016 is as follows: Shares Weighted Average Exercise Price Weighted average remaining contractual term (years) Aggregate Intrinsic Value Options outstanding, July 31, 2015 378,750 $ 0.38 Options granted – $ 0.000 Options exercised – $ 0.000 Options expired 178,750 $ 0.000 Options outstanding, July 31, 2016 200,000 $ 0.430 Options granted – $ – Options exercised – $ – Options expired 200,000 $ 0.430 Options outstanding, July 31, 2017 – $ – – $ – Options expected to vest, July 31, 2017 – $ – – $ – Options exercisable, July 31, 2017 – $ – – $ –

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Jul. 31, 2017
Debt Disclosure [Abstract]
Schedule of Credit Facility and Promissory Notes to Future Principal Payments	As of the date these financial statements are issued, the Company was obligated under the above described Credit Facility and Promissory Notes to make future principal payments (excluding interest) as follows: Year Ending July 31, 2018 1,925,000 $ 1,925,000

Basic and Diluted Loss Per Sh24

Basic and Diluted Loss Per Share (Tables)	12 Months Ended
	Jul. 31, 2017
Earnings Per Share [Abstract]
Schedule of Common Shares Not Included in Calculation of Diluted Net Loss Per Share	Potential common shares not included in calculating diluted net loss per share are as follows: July 31, 2017 July 31, 2016 Stock options – 200,000 Series C Preferred Stock 1,551,200 1,551,200 Series D Preferred Stock 13,910,000 13,910,000 Total 15,461,200 15,661,200

Long-Lived Assets (Tables)

Long-Lived Assets (Tables)	12 Months Ended
	Jul. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Long Lived Assets Held-for-Sale	Tooling and equipment, net of accumulated depreciation, consisted of the following at July 31, 2017 and 2016 (in thousands): Estimated Useful Life July 31, 2017 July 31, 2016 Furniture and fixtures, leasehold improvements, office equipment and computers 3 – 5 years $ 85 $ 85 Website and software 3 years 26 26 111 111 Less accumulated depreciation (111 ) (111 ) Tooling and equipment, net $ 0 $ 0

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Federal Income Tax Rate and Income Taxes	The difference between income taxes at the statutory federal income tax rate and income taxes reported in the consolidated comprehensive statements of operations are attributable to the following (in thousands): July 31, 2017 July 31, 2016 Income tax benefit at the federal statutory rate $ (166 ) $ (252 ) State and local income taxes, net of effect of federal taxes 10 (27 ) Stock-based compensation 272 – (Decrease) Increase in valuation allowance (116 ) 279 Provision for income tax $ – $ –
Schedule of Deferred Tax Assets	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets consist of the following (in thousands): July 31, 2017 July 31, 2016 Federal and State net operating loss $ 5,988 $ 5,847 Foreign net operating loss 18 18 Stock-based compensation and other 173 430 6,179 6,295 Less: Valuation allowance (6,179 ) (6,295 ) Net deferred tax asset $ – $ –

Organization and Business (Deta

Organization and Business (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Net income (loss)	$ (488)	$ (741)
Accumulated deficit	26,018	$ 25,530
Sing Lin [Member]
Accounts payable	$ 41

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Cash	$ 11	$ 87	$ 40
Advertising and promotional costs	0	0
Warranty costs	$ 0	$ 0
Exer-Rest Products [Member] | U.S. [Member]
Product warranties period	2 years
Exer-Rest Products [Member] | Outside U.S. [Member]
Product warranties period	1 year
Minimum [Member]
Income tax examination year under examination	2,013
Maximum [Member]
Income tax examination year under examination	2,017

Inventories (Details Narrative)

Inventories (Details Narrative) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Inventory valuation adjustments	$ 99	$ 327
Exer Rest Units [Member]
Inventory valuation adjustments	$ 99	$ 327

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Inventory Disclosure [Abstract]
Work-in-progress, including accessories and spare parts
Finished goods		99
Total inventories		$ 99

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Nov. 30, 2011
Share-based compensation options forfeited or expired
Unrecognized costs related to outstanding stock options
2011 Stock Incentive Plan [Member]
Maximum number of shares authorized for issuance under the plan			4,000,000
2000 Stock Option Plan [Member]
Maximum number of shares authorized for issuance under the plan	2,000,000
2000 Stock Option Plan [Member]
Share-based compensation, Description	The exercise price of the options is determined by the compensation committee of the Company’s Board of Directors, but incentive stock options, if any, must be granted at an exercise price not less than the fair market value of the Company’s common stock as of the grant date or an exercise price of not less than 110% of the fair value for a 10% shareholder.
2000 Stock Option Plan [Member] | Maximum [Member]
Options expire term	10 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Share-based Compensation Stock Options Activity (Details) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options outstanding shares, beginning balance	200,000	378,750
Options granted
Options exercised
Options expired	200,000	178,750
Options outstanding shares, ending balance		200,000
Options expected to vest, shares
Options exercisable, shares
Weighted average exercise price options outstanding, beginning balance	$ 0.430	$ 0.38
Weighted average exercise price options granted	0	0
Weighted average exercise price options exercised	0	0
Weighted average exercise price options expired	0.430	0
Weighted average exercise price options outstanding, ending balance	0	$ 0.430
Weighted average exercise price options expected to vest	0
Weighted average exercise price options exercisable	$ 0
Weighted average remaining contractual term (years) options outstanding	0 years
Weighted average remaining contractual term (years) options expected to vest	0 years
Weighted average remaining contractual term (years) options exercisable	0 years
Aggregate intrinsic value options outstanding
Aggregate intrinsic value options expected to vest
Aggregate intrinsic value options exercisable

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($) $ in Thousands

Apr. 06, 2017

Jun. 01, 2016

Oct. 27, 2015

Aug. 12, 2015

Apr. 16, 2015

Feb. 02, 2015

Sep. 24, 2014

Feb. 22, 2013

May 30, 2012

Sep. 12, 2011

Mar. 31, 2010

Jul. 31, 2017

Jul. 31, 2016

Short-term Debt [Line Items]

Proceeds from unrelated third party

$ 100

$ 325

Frost Gamma Investment Trust [Member] | 2011 Promissory Notes [Member]

Short-term Debt [Line Items]

Beneficial ownership percentage

10.00%

Aggregate principal amount

$ 50

Debt instrument maturity date

Jul. 31, 2018

Debt instrument interest rate

11.00%

Proceeds from unrelated third party

$ 100

Frost Gamma Investment Trust [Member] | 2015 Promissory Note [Member]

Short-term Debt [Line Items]

Beneficial ownership percentage

10.00%

10.00%

10.00%

Aggregate principal amount

$ 50

$ 25

$ 100

Debt instrument maturity date

Jul. 31, 2018

Jul. 31, 2018

Jul. 31, 2018

Debt instrument interest rate

11.00%

11.00%

11.00%

Frost Gamma Investment Trust [Member] | 2016 Promissory Note [Member]

Short-term Debt [Line Items]

Beneficial ownership percentage

10.00%

Aggregate principal amount

$ 100

Debt instrument maturity date

Jul. 31, 2018

Debt instrument interest rate

11.00%

Hsu Gamma Investments L P [Member] | 2012 Promissory Note [Member]

Short-term Debt [Line Items]

Aggregate principal amount

$ 50

Debt instrument maturity date

Jul. 31, 2018

Debt instrument interest rate

11.00%

Jane Hsiao [Member] | 2013 Promissory Note [Member]

Short-term Debt [Line Items]

Aggregate principal amount

$ 50

Debt instrument maturity date

Jul. 31, 2018

Debt instrument interest rate

11.00%

Jane Hsiao [Member] | 2014 Promissory Note [Member]

Short-term Debt [Line Items]

Aggregate principal amount

$ 50

Debt instrument maturity date

Jul. 31, 2018

Debt instrument interest rate

11.00%

Jane Hsiao [Member] | 2015 Promissory Note [Member]

Short-term Debt [Line Items]

Aggregate principal amount

$ 50

$ 50

Debt instrument maturity date

Jul. 31, 2018

Jul. 31, 2018

Debt instrument interest rate

11.00%

11.00%

Hsu Gamma [Member] | 2016 Promissory Note [Member]

Short-term Debt [Line Items]

Aggregate principal amount

$ 100

Debt instrument maturity date

Jul. 31, 2018

Debt instrument interest rate

11.00%

Hsu Gamma [Member] | 2017 Promissory Notes [Member]

Short-term Debt [Line Items]

Aggregate principal amount

$ 50

Debt instrument maturity date

Jul. 31, 2018

Debt instrument interest rate

11.00%

Hsu Gamma [Member] | 2017 Promissory Notes [Member] | September 22, 2017 [Member]

Short-term Debt [Line Items]

Aggregate principal amount

$ 50

Debt instrument maturity date

Jul. 31, 2018

Debt instrument interest rate

11.00%

Frost Gamma [Member] | 2017 Promissory Notes [Member]

Short-term Debt [Line Items]

Beneficial ownership percentage

10.00%

Aggregate principal amount

$ 50

Debt instrument maturity date

Jul. 31, 2018

Debt instrument interest rate

11.00%

Frost Gamma [Member] | 2017 Promissory Notes [Member] | September 22, 2017 [Member]

Short-term Debt [Line Items]

Beneficial ownership percentage

10.00%

Aggregate principal amount

$ 50

Debt instrument maturity date

Jul. 31, 2018

Debt instrument interest rate

11.00%

2010 Credit Facility [Member] | Frost Gamma and Hsu Gamma [Member]

Short-term Debt [Line Items]

Beneficial ownership percentage

10.00%

Aggregate principal amount

$ 1,000

Debt instrument maturity date

Jul. 31, 2018

Debt instrument interest rate

11.00%

2010 Credit Facility [Member] | Frost Gamma and Hsu Gamma [Member] | Maximum [Member]

Short-term Debt [Line Items]

Debt instrument interest rate

16.00%

Credit Facility [Member]

Short-term Debt [Line Items]

Line of credit facility outstanding

$ 1,000

$ 1,000

Notes Payable - Schedule of Cre

Notes Payable - Schedule of Credit Facility and Promissory Notes to Future Principal Payments (Details) $ in Thousands	Jul. 31, 2017USD ($)
Debt Disclosure [Abstract]
2,018	$ 1,925
Total	$ 1,925

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - $ / shares	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference	$ 100
Dividends payable amount per share	10
Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference	1
Dividends payable amount per share	0.10
Preferred stock, redemption price per share	$ 0.10
Convertible preferred stock, shares issued upon conversion	25
Preferred stock conversion premium price per share	$ 4.20
Preferred stock, conversion basis	Each share of Series C Preferred Stock is convertible into 25 shares
Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference	$ 1,500
Convertible preferred stock, shares issued upon conversion	5,000	65,000
Preferred stock, conversion basis	Each share of Series D Preferred Stock is convertible into 5,000 shares of the Company's common stock.
Conversion of stock, shares converted		13

Basic and Diluted Loss Per Sh36

Basic and Diluted Loss Per Share - Schedule of Common Shares Not Included in Calcutation of Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Class of Stock [Line Items]
Total	15,461,200	15,661,200
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Total	1,551,200	1,551,200
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Total	13,910,000	13,910,000
Stock Options [Member]
Class of Stock [Line Items]
Total		200,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jan. 01, 2008	Feb. 29, 2016	Feb. 28, 2016	Feb. 01, 2009	Jul. 31, 2017	Jul. 31, 2016
Related Party Transaction [Line Items]
Selling, general and administrative costs and expenses					$ 201,000	$ 259,000
Rent expenses			$ 0
Operating leases, rent expense		$ 0			44,000	52,000
Credit Facility [Member]
Related Party Transaction [Line Items]
Interest expense					110,000	110,000
Accrued interest					1,000,000	810,000
Promissory Notes [Member]
Related Party Transaction [Line Items]
Interest expense					83,000	59,000
Accrued interest					1,000,000	810,000
TransEnterix, Inc [Member]
Related Party Transaction [Line Items]
Accounts payable, related parties					800	800
Miami Lease [Member]
Related Party Transaction [Line Items]
Lease term	5 years
Lease expire date	Dec. 31, 2012
Payments for Rent	$ 1,250
Operating leases, rent expense					0	9,000
Rent payable					76,000	76,000
Dr Phillip Frost [Member]
Related Party Transaction [Line Items]
Beneficial ownership percentage	10.00%
Hialeah Lease [Member]
Related Party Transaction [Line Items]
Lease term				3 years
Lease expire date				Jan. 31, 2012
Payments for Rent				$ 5,000
Operating leases, rent expense					0	0
Rent payable					115,000	115,000
TransEnterix, Inc [Member]
Related Party Transaction [Line Items]
Selling, general and administrative costs and expenses					$ 5,000	$ 5,000

Commitments (Details Narrative)

Commitments (Details Narrative) $ in Thousands	Sep. 04, 2007USD ($)	Feb. 29, 2016USD ($)	Jul. 31, 2017USD ($)ft²	Jul. 31, 2016USD ($)
Operating leases, rent expense		$ 0	$ 44	$ 52
Area of land | ft²			4,000
Lease expiration date description			The lease commenced September 15, 2014 and originally expired on September 30, 2015 and we have exercised our options to renew that extends the expiration to September 15, 2017.
Manufacturing costs	$ 471
Cost of utilities	150
Payments on approval of product prototype concepts and designs	$ 150
Payments to suppliers			$ 1,700
Purchase obligation			13,900
Exer Rest Units [Member]
Purchase obligation, due in next twelve months			2,600
Purchase obligation, due in second year			4,100
Purchase obligation, due in third year			8,800
Sing Lin [Member]
Payables to customers			$ 41

Long-Lived Assets (Details Narr

Long-Lived Assets (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0	$ 0

Long-Lived Assets - Schedule of

Long-Lived Assets - Schedule of Long Lived Assets Held-for-Sale (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Long Lived Assets Held-for-sale [Line Items]
Tooling and equipment, gross	$ 111	$ 111
Less accumulated depreciation	(111)	(111)
Tooling and equipment, net	0	0
Furniture and Fixtures Leasehold Improvements Office Equipment and Computers [Member]
Long Lived Assets Held-for-sale [Line Items]
Tooling and equipment, gross	$ 85	85
Furniture and Fixtures Leasehold Improvements Office Equipment and Computers [Member] | Minimum [Member]
Long Lived Assets Held-for-sale [Line Items]
Estimated Useful Life	3 years
Furniture and Fixtures Leasehold Improvements Office Equipment and Computers [Member] | Maximum [Member]
Long Lived Assets Held-for-sale [Line Items]
Estimated Useful Life	5 years
Website and Software [Member]
Long Lived Assets Held-for-sale [Line Items]
Estimated Useful Life	3 years
Tooling and equipment, gross	$ 26	$ 26

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Income tax likehood percentage description	greater than 50 percent
Deferred tax assets, valuation allowance	$ 6,179	$ 6,295
Increases in the valuation allowance	116	$ 279
Federal and State Tax Authority [Member]
Operating loss carryforwards	15,900
Federal and State Tax Authority [Member] | Stock Options [Member]
Operating loss carryforwards	2,000
Foreign Tax Authority [Member]
Operating loss carryforwards	$ 100
Minimum [Member]
Income tax examination year under examination	2,013
Minimum [Member] | Federal and State Tax Authority [Member]
Income tax examination year under examination	2,013
Maximum [Member]
Income tax examination year under examination	2,017
Maximum [Member] | Federal and State Tax Authority [Member]
Income tax examination year under examination	2,016

Income Taxes - Schedule of Fede

Income Taxes - Schedule of Federal Income Tax Rate and Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Income Tax Disclosure [Abstract]
Income tax benefit at the federal statutory rate	$ (166)	$ (252)
State and local income taxes, net of effect of federal taxes	10	(27)
Stock-based compensation	272
(Decrease) Increase in valuation allowance	(116)	279
Provision for income tax

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Income Tax Disclosure [Abstract]
Federal and State net operating loss	$ 5,988	$ 5,847
Foreign net operating loss	18	18
Stock-based compensation and other	173	430
Deferred tax assets gross, total	6,179	6,295
Less: Valuation allowance	(6,179)	(6,295)
Net deferred tax asset